Toggle Nav
Close
  • Menu
  • Setting

Recombinant Murine Interleukin-36 beta, 153a.a.

Catalog No.
P1339
 
Grouped product items
SizePriceStock Qty
10ug
$247.00
Ship with 5-10 days
100ug
$1,692.00
Ship with 5-10 days
500ug
$3,795.00
Ship with 5-10 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Interleukin-36 is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. IL-36 beta has two isoforms. IL-36β2 contains one potential N-linked glycosylation site in its C-terminus, while IL -36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Within the IL-1 family, IL-36β/IL-1F8 shares 30 %, 32 %, 37 %, 46 %, 34 %, 45 % and 28 % a.a. sequence identity with IL-1 ra, IL-1β, IL-36Ra/IL-1F5, IL-36α/IL-1F6, IL-37/IL-1F7, IL-36γ/IL-1F9 and IL-1F10, respectively.

Reference

1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25

2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973

3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80

4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6

5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22.

Information

Gene ID69677
Accession #Q9D6Z6
Alternate NamesFIL1 eta, IL-1 eta, IL-1F8, IL-1H2
SourceEscherichia coli.
M.WtApproximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids.
AA SequenceSSQSPRNYRV HDSQQMVWVL TGNTLTAVPA SNNVKPVILS LIACRDTEFQ DVKKGNLVFL GIKNRNLCFC CVEMEGKPTL QLKEVDIMNL YKERKAQKAF LFYHGIEGST SVFQSVLYPG WFIATSSIER QTIILTHQRG KLVNTNFYIE SEK
AppearanceSterile Filtered White lyophilized (freeze-dried) powder.
Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
FormulationLyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4, 5% trehalose.
ReconstitutionWe recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Biological ActivityFully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105IU/mg.
Shipping ConditionGel pack.
HandlingCentrifuge the vial prior to opening.
UsageFor Research Use Only! Not to be used in humans.

Quality Control

Quality Control & DataSheet

View current batch:
    Purity > 97 % by SDS-PAGE and HPLC analyses.
    Endotoxin: Less than 1 EU/µg of rMuIL-36β, 153a.a. as determined by LAL method.
  • Datasheet